Cardiac Biomarkers have become essential tools for diagnosing, risk stratifying, and monitoring a wide range of cardiovascular conditions. This session provides a structured overview of key biomarkers—including troponins, natriuretic peptides, inflammatory markers, and emerging molecules—and explains how to apply them in emergency, inpatient, and outpatient settings. Participants will learn how to interpret dynamic changes over time, differentiate acute from chronic elevations, and combine biomarker data with clinical evaluation and imaging. The goal is to support precise, evidence-based decisions rather than relying on numbers in isolation.

Clinicians often search for a cardiology conference to stay current on rapidly evolving assay technologies and cut-offs. This session reviews high-sensitivity troponin assays, emphasizing how they have transformed the evaluation of chest pain and suspected acute coronary syndromes. Attendees will explore rule-in and rule-out algorithms, sex-specific thresholds, and strategies for avoiding over-diagnosis of myocardial injury. The session also covers natriuretic peptides in heart failure care, C-reactive protein and other inflammatory markers in risk assessment, and specialized tests used in cardiomyopathies and cardio-oncology.

A major focus is on integrating high-sensitivity troponin and other biomarkers into cohesive diagnostic and management pathways. Participants will examine how to design local protocols for chest pain units, emergency departments, and observation wards that use biomarkers to shorten length of stay while maintaining safety. Case examples will highlight common pitfalls—such as interpreting elevated troponins in renal failure, sepsis, or tachyarrhythmias—and how to distinguish myocardial infarction from non-ischemic injury. Guidance is also provided on communicating results to patients in understandable terms and avoiding unnecessary anxiety.

The session concludes by exploring future directions in biomarker research, including multi-marker panels, genomics-based risk tools, and the integration of lab data with AI-powered decision support. Attendees will consider how to evaluate new tests critically and decide when they add value beyond established markers. By the end, participants will have a clearer framework for using cardiac biomarkers judiciously to support timely, accurate, and patient-centered cardiovascular care.